Mirtazapina Eg (Mirtazapine)

Mirtazapine, the active ingredient in Mirtazapina Eg, is a noradrenergic and specific serotonergic antidepressant (NaSSA) presented as an oral tablet for oral use. It is prescribed for the treatment of major depressive disorder in adult patients, helping to improve mood, sleep and appetite.

GNH USA supplies Mirtazapina Eg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing consistent quality, regulatory compliance and reliable delivery across global markets.

Mirtazapine is indicated for several depressive and related conditions, acting on central neurotransmitter pathways.

- Major Depressive Disorder: reduces depressive symptoms and improves overall mood in adult patients. - Depressive Episodes in Bipolar I Disorder: alleviates depressive phases when used as adjunct therapy. - Anxiety Associated with Depression: helps lessen anxiety symptoms that coexist with depressive illness.

Mirtazapine may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Constipation - Dizziness - Fatigue

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Suicidal thoughts or behavior, especially early in treatment - Severe rash or hypersensitivity reactions - Hepatic dysfunction - Seizures - Unexplained bleeding or bruising

Before initiating therapy, clinicians should evaluate individual risk factors and monitor patients regularly.

- Assess psychiatric history: evaluate risk of suicidal ideation before starting treatment. - Monitor weight: watch for significant weight gain during therapy. - Check liver function: obtain baseline hepatic labs and repeat as indicated. - Avoid abrupt discontinuation: taper under medical supervision to reduce withdrawal effects. - Use caution in elderly: increased sensitivity to sedation and orthostatic hypotension. - Store at room temperature: keep in the original pack, protect from moisture and light.

Mirtazapine can interact with several drug classes; awareness helps prevent adverse outcomes.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of serotonin syndrome. - Strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may increase mirtazapine plasma levels. - Central nervous system depressants (alcohol, benzodiazepines): enhanced sedation and respiratory depression.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: additive dry mouth and constipation. - Warfarin: potential alteration of INR, requiring closer monitoring. - Carbamazepine: may reduce mirtazapine concentrations, affecting efficacy.